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Abstract
The role of vascular endothelial growth factor receptor 1 (VEGFR1/Flt1) in tumor metastasis remains incompletely
characterized. Recent reports suggested that blocking VEGFR1 activity or the interaction with its ligands (VEGF and PlGF)
has anti-tumor effects. Moreover, several studies showed that VEGFR1 mediates tumor progression to distant metastasis. All
these effects may be exerted indirectly by recruitment of bone marrow-derived cells (BMDCs), such as myeloid cells. We
investigated the role of VEGFR1 activity in BMDCs during the pre-metastatic phase, i.e., prior to metastatic nodule formation
in mice after surgical removal of the primary tumor. Using pharmacologic blockade or genetic deletion of the tyrosine
kinase domain of VEGFR1, we demonstrate that VEGFR1 activity is not required for the infiltration of de novo myeloid BMDCs
in the pre-metastatic lungs in two tumor models and in two mouse models. Moreover, in line with emerging clinical
observations, we show that blockade of VEGFR1 activity neither prevents nor changes the rate of spontaneous metastasis
formation after primary tumor removal. Prevention of metastasis will require further identification and exploration of cellular
and molecular pathways that mediate the priming of the metastatic soil.
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Introduction
VEGF, and more recently, PlGF, have been shown to play
important roles in tumor angiogenesis in preclinical studies.
Moreover, VEGF is a clinically validated target for antiangio-
geneic therapy for cancer, and agents that block PlGF or the
tyrosine kinase activity of their cognate receptor VEGFR1 are
currently approved for cancer treatment or in clinical trials
(sunitinib, sorafenib, cediranib, axitinib, pazopanib, BIBF1120,
etc.) [1,2,3]. In addition to the roles of VEGFR1 activation in
tumor endothelial cells, it has been hypothesized that VEGFR1
activation mediates the mobilization of bone marrow-derived cells
(BMDCs) into blood circulation [4]. Other studies have shown
that BMDCs are recruited to certain tumors and facilitate tumor
progression [5,6]. A recent study demonstrated that PlGF, a ligand
for VEGFR1 as well as Neuropilins 1 and 2 (NRP1/2),
significantly modulated the recruitment of macrophages, tumor
growth and local invasion [7]. On the other hand, blockade of
VEGFR1 did not affect BMDC accumulation or growth of
pancreatic endocrine tumors [8]. Moreover, VEGFR1 blockade
may differentially affect the recruitment of various BMDC
populations in tumors. For example, cediranib, an agent that
potently inhibits VEGFR1 activity, transiently reduced macro-
phage infiltration but increased the total number of myeloid
(CD11b
+) cells and did not delay the growth rate of brain tumors
[9]. Thus, the benefit of targeting VEGFR1 activity remains
unclear, and is likely to be highly tumor–, BMDC type– and
context-dependent.
In addition to effects at the primary tumor site, blockade of
VEGFR1 has been proposed as an anti-metastasis approach.
Previous studies in flt1-tk deficient mice have shown that MMP-9
is induced by VEGFR1 signaling in lung cells and facilitates
metastatic tumor growth in experimental metastasis models (i.e.,
after intravenous infusion of cancer cells). Moreover, it has been
recently reported that BMDCs – systemically mobilized in
response to primary tumor growth – home to the lungs and form
‘‘pre-metastatic niches’’ in lungs even prior to the arrival of
metastatic cancer cells [10]. A critical mediator of myeloid
(CD11b
+) BMDC recruitment to the ‘‘pre-metastatic niche’’ was
shown to be hypoxia-induced lysyl oxidase [11]. Hypoxia is known
to induce VEGF, PlGF, and their cognate receptor VEGFR1
[1,12]. In a recent study, blockade of VEGFR1 with a specific
antibody, MF1 (ImClone Systems, Inc.) has been shown to inhibit
lung infiltration by BMDCs, subsequent ‘‘pre-metastatic niche’’
formation and metastatic tumor growth [10].
Spontaneous metastasis formation can be induced in preclinical
models by surgically removing metastatic primary tumors
[13,14,15,16]. This model, relevant for resectable human cancers,
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including the role of BMDCs [13,14]. In this model, we found that
blockade of VEGFR1 activity did not affect the rate of
spontaneous metastasis formation after primary tumor removal
[17]. Here, we show that myeloid (CD11b
+) BMDCs (e.g.,
pulmonary alveolar macrophages), are present in normal lungs
and that VEGFR1 blockade does not modulate their infiltration in
the presence of primary tumors prior to metastasis formation. On
the other hand, we show that BMDCs may be affected by
VEGFR1 activity blockade at later time-points, i.e., during
metastatic tumor growth. Thus, while VEGFR1 activity is not
required for the formation of metastatic tumor nodules, its
blockade may differentially modulate the BMDC infiltration and
growth of primary tumors and metastatic nodules.
Materials and Methods
Mice
C57BL and Actb-GFP/C57BL mice (constitutively expressing
GFP) were obtained from the Jackson Laboratory (Bar Harbor,
Maine). Flt-1
TK–/–/C57BL mice were backcrossed to 99.9%
C57BL strain background (N10 equivalent) from flt-1
TK–/– mice
[18,19], kindly provided by Dr. M. Shibuya, University of Tokyo,
Japan. Strain background was verified by the Jackson Laboratory’s
Speed Congenic Development Service (The Jackson Laboratory,
Bar Harbor, Maine). All mice were bred and maintained in sterile
barrier animal facilities. All flt-1
TK–/–/C57BL mice were used for
experiments after genotyping to confirm the deletion of the
intracellular domain of VEGFR1. All animal experiments were
performed after obtaining approval from the Subcommittee for
Research and Animal Care of the Massachusetts General Hospital.
Bone Marrow Transplantation
C57BL mice (6–7 weeks old, male) were lethally irradiated
(
137Cs Irradiator; Atomic Energy of Canada Ltd, Mississauga,
Canada) using two 6 Gy fractions (with less than 12 hour time
interval between dosing) delivered to the whole body. Irradiated
mice were rescued 24 hours later by a bone marrow transplant
isolated from Actb-GFP/C57BL, as previously described [13]
(Figure 1A). We used the model after confirming that no weight
loss or fibrosis, inflammation or any other sign of damage was
detectable in the lungs two months after BMT. The BMT protocol
was also optimized to ensure reproducible levels of GFP
+ BMDC
chimerism in BMT-Actb-GFP/C57BL mice. Blood was collected at
four and eight weeks after BMT for flow cytometry analysis. To
limit the variability in GFP-BMDC chimerism, BMT mice were
prepared in large groups (32 recipient mice were injected with
pooled BM from 11 donor mice). One group was prepared for
each tumor model (see Figure 1B).
Tumor Cells
Lewis lung carcinoma (LLC1/LL2, CRL-1642) and B16
melanoma cell lines (CRL-6323) – both syngeneic to C57BL
mouse – were purchased from ATCC (Manassas, VA). Both cell
lines were propagated in DMEM (LLC1-ATCC/B16F1-Cellgro)
supplemented with 10% fetal bovine serum (Atlanta Biologicals,
Norcross, GA).
Tumor Growth and Metastasis Model
LLC1 or B16 cells were subcutaneously (s.c.) implanted in the
left leg of BMT-Actb-GFP/C57BL (8 weeks after BMT), flt-1
TK–/–/
C57BL or C57BL mice as a 50 ml concentrated cell solution
containing 300,000 cells in sterile PBS. Tumor growth was
measured with a caliper three times per week and tumor volume
(V) was calculated using the following formula (1):
V ~0:52 | tumor length | tumor width ðÞ
3=2 ð1Þ
Primary tumors were surgically resected when they reached a
diameter of 10 mm. Mice were sacrificed by pentobarbital
overdose (200 mg/kg administered by i.p. injection) at the time
of resection (i.e., day 0), or 10 or 14 days after resection to analyze
BMDC infiltration and metastatic nodule formation in the lungs
(see schema in Figure 1A). Prior to sacrifice, blood was collected
from anesthetized animals by cardiac puncture using a 26-G
needle. The lungs were washed by cardiac injection of 15 ml of
PBS, weighed and then examined using a dissecting microscope.
The number of macroscopic metastases was enumerated by
counting individual nodules with a cell counter. B16 metastases
are easily identifiable, in part due to their pigmentation (see
Figure 2). Primary tumor tissues and whole lungs were fixed in
4% paraformaldehyde at 4uC for 6 hours, dehydrated in 30%
sucrose overnight, and embedded in OCT into frozen samples for
immunofluorescence histological analyses.
Antibody Treatment
Tumor-bearing mice were administered i.p. MF1 blocking
monoclonal antibodies against VEGFR1 (a gift from ImClone
Systems, New York, NY) at a blocking dose of 20 or 40 mg/kg
three times per week (see Ref. [20]) from the time of tumor
implantation (Figure 1B). As a control, tumor-bearing mice were
treated i.p. 3 times per week with 20 mg/kg of non-specific rat
IgG (Jackson ImmounoResearch Laboratories, West Grove, PA).
To confirm MF1 inhibitory activity, we incubated mouse brain
endothelial cells (bEnd.3 cells) in serum free condition overnight.
After 1 hr of exposure with rat IgG (50 mg/ml) or MF1 (20 mg/ml
or 50 mg/ml), cells were stimulated with 100 ng/ml recombinant
mouse PlGF-2 (Minneapolis, MN) for 10 min. Then, the cells were
rinsed with cold PBS and collected using RIPA buffer supple-
mented with protease inhibitors (Roche, Nutley, NJ) and
phosphatase inhibitiors cocktail (Sigma, St. Louis, MO). Protein
extracts were incubated with anti-VEGFR1 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) overnight and VEGFR1 was
precipitated using protein A agarose. Immunoprecipitates were
separated on denaturing gel and transferred to PVDF membrane.
Phosphotyrosine was detected using anti-phosphotyrosine anti-
body (Millipore, Billerica, MA). The membrane was then stripped
and re-probed with anti-VEGFR1 antibody (Figure 1C).
Histological Analysis
Frozen tumor and lung tissue samples were cryosectioned into
10-20 mm slices. Tissue sections were immunostained with
monoclonal antibodies against CD11b-PE, F4/80-PE, and CD31-
APC (all from BD Pharmingen, San Diego, CA). For VEGFR1
staining, we used MF1 antibodies labeled with Alexa-Flour-647
(Molecular Probes, Carlsbad, CA). All tissue sections were mounted
on glass coverslips using VectashieldH mounting media with DAPI
from Vector Labs (Burlingame, CA). For quantitative analysis, we
collected 6–12 random 8-bit images per section of lung (6 per region
of the lung, including lung metastasis and tissue surrounding
metastasis) and tumortissue (6 imagesof the periphery and 6 images
of the center) (102461024 pixels), using a confocal microscope
(Olympus, Center Valley, PA) and a 206 water-immersion lens
(0.95NA). For each image, we determined the area occupied by
GFP-positive BMDCs or immunostained cells normalized by area
of DAPI-stained cells (nuclear counterstaining) using an algorithm
VEGFR1-Independent Metastasis
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e6525Figure1. Experimental design. (A) Timeline for spontaneous metastasis studies: C57BL mice were lethally irradiated and transplanted 24 hours later
with bone marrow cells isolated from Actb-GFP/C57BL mice (BMT). BMT mice were allowed to recover for 8 weeks prior to study. LLC1 or B16 tumor cells
(TCs) weresubcutaneously (s.c.)implantedintheleft leg.ThreedaysafterLLC1 orB16injectionanduntilsacrifice,miceweretreated3 timesperweekby
intraperitoneal (i.p.) injection of rat IgG (control) or VEGFR1-blocking antibody (MF1, 20 mg/kg). Primary tumors were resected when they reached a
maximum length of 10 mm. Lung tissue was isolated from mice at three time points: at time of primary tumor resection and 10 and 14 days after
removal of the primary tumor. Note: Tumor growth varied from 13–17 days; no macroscopic metastases are detectable at days 0 or 10 after tumor
resection. (B) Bone marrow chimerism (each blue line represents GFP
+ BMDCs in one BMT mouse, 30 mice prepared in one BMT procedure). Blood flow
cytometric analysis was used to enumerate the percentage of GFP
+ BMDCs among nucleated blood cells. (C) Mouse brain endothelial cells treated with
rat IgG or MF1 were stimulated with 100 ng/ml of recombinant mouse PlGF-2 and incubated with anti-VEGFR1 antibody (MF1). VEGFR1 was
immunoprecipitated andthe ratio of phosphorylated-VEGFR1 to total VEGFR1 was compared to the ratio calculated for non-stimulated endothelial cells
(assigned the value of 1). MF1 inhibited VEGFR1 phosphorylation in endothelial cells after PlGF2 stimulation in a dose-dependent manner.
doi:10.1371/journal.pone.0006525.g001
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coverage area was calculated as a measure of cell number per tissue
area. We report the average of the mean values of GFP/DAPI ratio
for mouse lungs or tumors in each treatment group (6–7 lungs or
tumors per treatment group were included).
Flow Cytometric Analyses
Blood was collected from mice by cardiac puncture. Tumor
tissues were digested into a single cell suspension using collagenase
type II (Worthington, Lakewood, NJ) [13]. Cells were immuno-
stained with the following monoclonal antibodies: anti-CD11b-
APC, anti-Gr-1-FITC/PE, anti-CXCR4-PE, anti-CD45-PerCP
(all from BD Pharmingen) and MF1-Alexa-647. We used Fc-
blocking antibodies (BD Pharmingen) to block non-specific
binding and non-specific fluorescently labeled IgG as control.
Statistical analysis
Two-tailedunpaired studentst-tests (assumingunequal variances)
wereused to compare alltreatmentand control groupswithp,0.05
indicatinga statistical difference.The rate of spontaneous metastasis
formation in control and treatment groups was also compared using
the Mann-Whitney U test (Wilcoxon rank-sum test).
Results
Effect of VEGFR1 blockade on primary tumor growth
Continuous blockade of VEGFR1 with MF1 antibodies – from
the time of LLC1 or B16 implantation in BMT-Actb-GFP/C57BL
mice – did not delay primary tumor growth compared to non-
specific IgG (Figure S1A,B). Similarly, LLC1 tumor growth rate
was comparable in flt-1
TK–/–/C57BL to that in C57BL mice
(Figure S1C). The growth of B16 melanoma was delayed by an
average of 2 days in flt-1
TK–/–/C57BL compared to C57BL mice
(p,0.05, Figure S1D). Thus, blockade of VEGFR1 activity leads
to a slight or no growth delay in primary B16 and LLC1 tumors.
Since VEGFR1 is thought to modulate BMDCs recruitment to
tumors and metastasis, we measured next the number of
metastases that formed in the lungs after surgical removal of the
primary tumors.
Effect of VEGFR1 blockade on spontaneous metastasis
formation after primary tumor resection
We surgically removed the primary tumors – as per animal
protocol – when LLC1 and B16 tumors grew to 10-mm in
diameter (approximately 15–17 days after implantation). Two
weeks after resection of primary tumors, metastatic tumor nodules
were present in the lungs of all 17 mice bearing LLC1 tumors,
both after MF1 (n=9) and IgG (n=8) treatment (see data
reported in Ref. [17]). The metastatic nodules (with sizes estimated
as 1–3 mm, 3–5 mm, .5 mm) were counted using a dissecting
microscope (Figure 2). At this time-point, there were no
significant differences between the number nor the size of
metastatic nodules [17]. At the same time-point after resection
of primary B16 tumors, 9/12 mice treated with MF1 and 9/13
mice treated with IgG developed lung metastatic nodules. In mice
that developed macroscopic metastases, there was no significant
Figure 2. Effect of VEGFR1-blockade on metastasis. Representative images of lung metastases 14–16 days after resection of the primary tumor
and bone marrow-derived cell (BMDC) accumulation in the primary tumor, peri-metastatic lung (PML, tissue surrounding lung metastases) and lung
metastases in the LLC1 (A) and B16 (B) models. The number of BMDCs was calculated as the ratio of green fluorescence protein (GFP)-surface area to
DAPI-surface area. DAPI was used to stain the nuclei of all cells (n=6–8 mice per group). All images are 512 mm across.
doi:10.1371/journal.pone.0006525.g002
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and IgG-treated groups [17]. Thus, in this setting of neoadjuvant
and adjuvant VEGFR1 blockade (i.e., continuous blockade of
VEGFR1 using MF1 from the time of primary tumor implanta-
tion) did not significantly alter the rate of spontaneous macro-
scopic lung metastasis formation.
Next, we measured metastatic nodule formation after resection
of LLC1 or B16 primary tumors implanted in flt-1
TK–/–/C57BL
mice (mice which lack the tyrosine kinase domain but not the
extracellular domain [18]) or in C57BL mice. When evaluated at
14 days after primary LLC1 tumor resection, 12/13 flt-1
TK–/–/
C57BL mice and 6/8 C57BL mice had macroscopic lung
metastases. At the same time-point after B16 primary tumor
resection, 7/14 flt-1
TK–/–/C57BL mice and 6/8 C57BL mice had
metastatic nodules in the lung (see data reported in Ref. [17]).
Control and treatment groups were compared using student’s t-
tests and rank-sum tests (Mann-Whitney U), and differences in
metastatic tumor formation were not significant between groups.
Thus, genetic ablation of VEGFR1 activity did not result in
significantly different rate of formation of macroscopic lung
metastasis. Similarly, the number of spontaneous macroscopic
lung metastases formed 2 weeks after LLC1 or B16 resection was
not significantly different between flt-1
TK–/–/C57BL and C57BL
mice [17].
The number of circulating VEGFR1
+ and CXCR4
+ BMDCs
is tumor-dependent, but blockade of VEGFR1 activity
does not change BMDC accumulation in the primary
tumor
Several studies have shown that VEGFR1 modulates BMDC
infiltration in tumors, and that BMDCs are modulating metastasis.
Thus, we measured the accumulation of BMDCs in the primary
tumors and lungs after the formation of macroscopic metastases in
our model. Evaluation of blood cells in tumor-bearing flt-1
TK–/–/
C57BL and C57BL mice showed no significant difference between
circulating CD45
+, CD11b
+, Gr-1
+, VEGFR1
+ or CXCR4
+ cells
in these mice (Figure 3A). However, we detected significantly
more circulating VEGFR1
+ cells and significantly fewer circulat-
ing CXCR4
+ cells in C57BL mice bearing LLC1 tumors
compared to C57BL mice bearing B16 tumors. Next, we
investigated the intra-tumor accumulation of BMDCs. While
LLC1 or B16 cells do not express VEGFR1 (as evaluated by PCR,
data not shown), certain cells in the tumor stroma might express
VEGFR1 (e.g., endothelial cells). Thus, we performed flow
cytometric analysis of tumor stromal cells in LLC1 and B16
tumors after gating on the CD45
+ cell population. LLC1 tumors
contained more hematopoietic (CD45
+) cells than B16 tumor both
in flt-1
TK–/–/C57BL and C57BL mice. However, no statistically
significant differences were found among infiltrating hematopoi-
etic BMDCs positive for VEGFR1
+ cells, Gr-1 (granulocytes/
monocytes), F4/80 (macrophages) or CD11b (all myeloid cells) in
the tumors grown in flt-1
TK–/–/C57BL and C57BL mice
(Figure 3B).
VEGFR1-blocking antibody reduces the accumulation of
bone marrow-derived cells in the metastatic lesions and
peri-metastatic lung tissue, but not in the primary tumors
To establish with precision the BMDCs infiltration after
VEGFR1 blockade, we quantified the BMDCs in LLC1 and
B16 tumors implanted in BMT-Actb-GFP/C57BL mice after
treatment with MF1 at the time of resection (approximately 2
weeks after implantation). Antibody blockade of VEGFR1 – from
the time of implantation – did not change the number of GFP
+
BMDCs in primary LLC1 or B16 tumors (Figure 4A–B) [17].
However, when most mice spontaneously developed macroscopic
metastases (2 weeks after primary tumor resection), we detected a
significant increase in BMDC accumulation inside the LLC1
metastatic nodules and in the peri-tumor lung tissue, but not in
B16 metastases (Figures 2 and 4E,L). Thus, the reduction by
VEGFR1 blockade in BMDC accumulation in metastases is tumor
dependent. However, prior to the time-point used by us for
resection (days 14–16), BMDC ‘‘pre-metastatic niches’’ [10], and
metastatic foci [13] should have been formed in the lungs in these
tumor models. Thus, we measured the accumulation of BMDCs in
the lungs at the earlier time points (i.e., days 0 and 10 after
resection).
VEGFR1-blocking antibody does not reduce the baseline
accumulation of myeloid bone marrow-derived cells in
the pre-metastatic lungs
At the time of the primary tumor resection, as well as 10 days
after that, evaluation of lungs showed no macroscopic metastatic
tumor nodules. Nevertheless, BMDC infiltration at the time of
Figure 3. Flow cytometric analysis of circulating cells and
tumor-homing BMDCs in tumor-bearing mice. (A) Peripheral
blood from C57BL (black bars) and flt-1
TK–/–/C57BL (empty bars with
diagonal lines) mice were analyzed using antibodies for specific surface
markers (all cells were CD45
+). B, Flow cytometric analysis of
enzymatically digested LLC1 tumor suspensions from C57BL (black
bars, n=6) and flt-1
TK–/–/C57BL (empty bars with diagonal lines, n=6)
mice using antibodies for specific surface markers. There was no
statistically significant difference in the blood cell population studied in
C57BL and flt-1
TK–/–/C57BL nor in the number of hematopoietic cells
within the tumor tissues. However, there were significant inter-tumor
differences: mice with B16 tumors had significantly more CXCR4
+CD45
+
blood circulating cells than mice with LLC1 tumors (p,0.05 by
Student’s t-test). In addition, while B16 tumors recruited fewer CD45
+
cells, the fraction of VEGFR1
+CD45
+ cells was greater than in LLC1
tumors. A statistically significant difference (p,0.05 by Student’s t-test)
is identified with an asterisk.
doi:10.1371/journal.pone.0006525.g003
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models, and comparable with BMDC accumulation in tumor-free
BMT-Actb-GFP/C57BL mice (Figure 5). Thus, VEGFR1 block-
ade by MF1 treatment did not reduce BMDC infiltration in the
lungs prior to macroscopic metastases formation (i.e., at days 0 and
10) in mice that had primary tumors removed [17]. These BMDCs
were likely pulmonary alveolar macrophages, which reside in the
normal, non-irradiated lung in comparable numbers in tumor-free
non-BMT C57BL mice (Figure 6). To directly address the issue
of BMDC phenotype (Figure 7A,D), and to exclude the
possibility that inflammatory BMDCs infiltration in lungs was an
artifact due to prior whole body irradiation and BMT, we
performed CD11b (Mac1) and VEGFR1 immunostaining in
normal, non-irradiated C57BL and flt-1
TK–/–/C57BL mice. In the
lungs of these mice, we detected myeloid (CD11b
+) cells in
numbers comparable to those of lung infiltrating BMDCs in
BMT-Actb-GFP/C57BL mice. Moreover, the number of
VEGFR1
+ cells in the lung tissue was not significantly different
between C57BL and flt-1
TK–/–/C57BL mice (Figure 7B,E).
Next, we measured the number of CD11b
+ cells in spontaneous
metastatic nodules in flt-1
TK–/–/C57BL and C57BL mice formed
after primary tumor resection. Consistent with the effect of
antibody blockade of VEGFR1, we detected a significant decrease
in the number of CD11b
+ cells but not VEGFR1
+ cells in the peri-
tumor areas in LLC1 lung metastases from (non-irradiated) flt-
1
TK–/–/C57BL and C57BL mice (Figure 7C,F,G).
Discussion
VEGF is a clinically validated target in metastatic (advanced)
cancer treatment, but the mechanism(s) by which its blockade
leads to a clinical benefit remain unclear [3]. It is largely thought
that the benefit derives from blockade of the interaction between
VEGF and its receptor VEGFR2 on endothelial cells, which
mediates key functions in angiogenesis and vascular function [2].
But VEGF binds with a higher affinity to VEGFR1, which is
present on endothelial cells but also on inflammatory cells in
tumors or even on the malignant cells in certain tumors [1].
Recent studies of the VEGFR1 ligand PlGF have proposed that
VEGFR1 mediates tumor growth and angiogenesis by recruiting
tumor-promoting inflammatory cells [7]. Others have shown that
VEGFR1 signaling activation leads to MMP-9 expression in lung
Figure 4. Bone marrow-derived cell (BMDC) accumulation in the primary tumors, lung metastases and surrounding (peri-
metastatic) lung tissues after VEGFR1 blockade. Confocal images of cryo-sectioned primary tumor (A–D), peri-metastatic lung tissue (E–H) and
metastatic lung tumors (I–L) collected from BMT-Actb-GFP/C57BL mice (BMDCs are shown in green) after IgG (A, C, E, G, I, K) or MF1 (B, D, F, H, J,
L) treatment. Tissues were counterstained with DAPI nuclear dye (in blue). The width of images in A–J is 512 mm and images in K and L are 256 mm
across.
doi:10.1371/journal.pone.0006525.g004
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experimental metastasis [19]. Moreover, it has been proposed that
BMDC infiltration into lung tissue precedes the spontaneous
arrival of metastatic cancer cells, and that VEGFR1 expression on
the BMDCs mediates this process [10]. The direct implication is
that VEGFR1 blockade may prevent/eradicate metastasis of the
primary tumors to distant organs. Of note, a phase III of the anti-
VEGF antibody bevacizumab as adjuvant after surgery in patients
with colorectal cancer showed that VEGF blockade did not affect
metastasis formation or patients’ disease-free survival [21].
We sought to establish if blockade of VEGFR1 activity could
eradicate tumor progression to metastasis in a model mirroring the
neoadjuvant and adjuvant therapy of tumors (i.e., continuous
VEGFR1 blockade in mice from the time of implantation of the
primary tumor, including the period after resection of the primary
tumor when it has reached 1 cm in diameter and has seeded
metastatic cells in the lungs). None of the cancer cell lines used in
this study (LLC1 and B16) expressed detectable levels of
VEGFR1. In these models, we measured the spontaneous
formation of lung metastatic nodules. In addition, we studied
formation of lung metastatic nodules in a genetic model of
VEGFR1 deficiency (flt-1
TK–/–/C57BL mice, which lack tyrosine
kinase domain of VEGFR1). Since these mice express the
extracellular domain of VEGFR1, the ligands can bind to the
extracellular portion of the receptor, unlike when the MF1
antibodies are used (which completely block both ligand-receptor
interaction and downstream signaling). Consistent with published
reports on blockade of the VEGFR1 ligand PlGF, we found a
significantly decreased blood vessel density in primary LLC1
tumor after VEGFR1 blockade by MF1 treatment. However,
MF1 treatment did not decrease the number of BMDCs recruited
into primary LLC1 tumors, nor their growth rate. Moreover,
despite continued VEGFR1 blockade with MF1, metastatic
nodule formation rate was not affected in mice whose tumors
were resected when they reached 1 cm in diameter. These results
were confirmed using the spontaneous LLC1 metastasis in flt-
1
TK–/–/C57BL mice. In a second model, we evaluated B16
growth and spontaneous metastasis after primary tumor resection.
Similar to LLC1 tumors, tumor growth and spontaneous B16
metastatic nodule formation was not significantly affected by MF1
treatment from the time of tumor implantation. In flt-1
TK–/–/
C57BL mice, B16 primary tumor growth was significantly delayed
compared to C57BL, but spontaneous B16 metastatic nodule
formation after primary tumor resection was similar. The lack of
effects of VEGFR1 antagonism on the rate of spontaneous
metastasis is of particular interest in light of recent reports that
VEGF antagonism might lead to increased metastatic burden
[22,23].
Figure 5. Effect of VEGFR1-blockade on BMDC infiltration in lungs prior to macroscopic metastasis formation. Treatment of tumor
bearing mice with MF1 antibody did not change the infiltration with BMDCs in lungs at the time of primary tumor resection (day 0) or 10 days after
primary tumor removal. Representative images of lung tissue from non-tumor bearing C57BL (A) and BMT-Actb-GFP/C57BL (B) mice and from LLC1-
tumor bearing mice at the time of primary tumor resection (day 0) after treatment with IgG (C) or MF1 (D). The number of BMDCs was calculated as
the ratio of green fluorescence protein (GFP)-surface area to DAPI-surface area (E). DAPI was used to stain the nuclei of all cells (n=6–8 mice per
group). All images are 512 mm across.
doi:10.1371/journal.pone.0006525.g005
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effects of anti-PlGF on the primary B16 tumors and lymphatic
metastasis [7]. Data from our own experiments using PlGF blockade
(Dawson et al., unpublished observations) are consistent with the
results in this report [7], and suggest that the antiangiogenic effect in
primary tumors may account for the effects of PlGF blockade on
lymphatic metastasis and lung metastasis. It is important to note that
in this case the blockade of the ligand (i.e., PlGF) may affect not only
VEGFR1 activity, but also NRP1 and NRP2 [1].
We used the similar regimen for MF1 treatment, similar cell lines
and similar mouse strain as Kaplan et al. [10]. At this dose, MF1
was ‘‘biologically active’’ since it significantly inhibited PlGF-
induced VEGFR1 phosphorylation in vitro. Moreover, MF1
treatment significantly inhibited BMDC accumulation in and
around growing metastatic nodules in vivo. Nevertheless, VEGFR1
activity blockade did not change BMDC/CD11b
+ cell accumula-
tion in pre-metastatic lungs. This may point toward a key role of the
resident pulmonary alveolar macrophages in the pre-metastatic
phase as opposed to de novo BMDC recruitment. The lack of effect of
MF1 treatment on tumor angiogenesis and inflammatory cell
infiltration has been well established for spontaneous tumors (e.g.,
pancreatic insulinoma, see Ref. [8]). In models in which an anti-
tumor effect for VEGFR1 blockade was detected, they were
attributed to direct effects on cancer cells or by modulation of
Figure 6. Representative images and analysis of CD11b and MF1 staining of normal lung tissue. (A–H) Confocal microscopy images of
lung tissue from C57BL (A–D, non-irradiated, non-GFP control) and BMT-Actb-GFP/C57BL (E–H, irradiated mice, GFP
+ BMDCs shown in green) mice
stained with CD11b-AF546 (red) and MF1-AF647 (yellow) and counterstained with DAPI nuclear dye (blue). The number of GFP, CD11b, or MF1
positive cells was calculated as a ratio of green, red, or yellow surface area to DAPI surface area, respectively (I). All images are 512 mm across.
doi:10.1371/journal.pone.0006525.g006
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PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e6525angiogenesis [20,24], but there was no data reported on
hematogenous metastasis formation. This may be related to cell
migration and MMP-9 activity in response to VEGFR1 activation
in resident pulmonary macrophages and/or endothelial cells [19].
The regulation of tumor angiogenesis by VEGFR1 may be
direct or indirect (related to BMDC recruitment) [1,4]. Given the
lack of modulation of metastatic nodule formation by VEGFR1 in
our models, we evaluated the kinetics of BMDC infiltration in
Figure 7. Representative images and quantification of CD11b and VEGFR1 positive cells at the periphery of lung metastases. (A–F)
Confocal microscopy images of lung tissue from C57BL mice (WT, A–C) and flt-1
TK–/–/C57BL (KO, D–F) mice after immunostaining for CD11b (using
FITC-labeled anti-CD11b antibody, in green in B and E), or for VEGFR1 (using AF647-labeled MF1 antibody, in red in C and F). Sections were
counterstained with DAPI nuclear dye (in blue in A–F). The number of positive cells was calculated as the ratio of CD11b
+ or VEGFR1
+ surface area to
DAPI surface area (G). A statistically significant difference (p,0.05 by Student’s t-test) is identified with an asterisk. All images are 512 mm across.
doi:10.1371/journal.pone.0006525.g007
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PLoS ONE | www.plosone.org 9 September 2009 | Volume 4 | Issue 9 | e6525lungs prior to and after macroscopic metastatic nodule formation.
We found no significant difference after blockade of VEGFR1
activity in BMDC infiltration in lungs prior to macroscopic
metastasis formation. BMDC infiltration in BMT-Actb-GFP/
C57BL mice was similar the CD11b
+ cell infiltration in non-
irradiated C57BL mice. Moreover, MF1 treatment did not
significantly change the number of BMDCs in the pre-metastatic
lungs of mice. This lack of modulation of BMDC infiltration in
normal lungs was confirmed in flt-1
TK–/–/C57BL mice, which had
comparable CD11b
+ cell numbers (most likely pulmonary alveolar
macrophages) in pre-metastatic lungs. Nevertheless, after the onset
of metastatic nodule growth, MF1 blockade of VEGFR1 led to a
partial decrease in BMDC infiltration inside and around LLC1
metastatic nodules, which is consistent with modulation by
VEGFR1 activity of BMDC accumulation in some tumors during
their growth. Of note, despite the significant reduction, the BMDC
accumulation was not completely blocked, and remained quite
high, suggesting that BMDC accumulation in growing metastatic
nodules is only partially controlled by VEGFR1 signaling. In
growing B16 tumors, which have low levels of BMDC infiltration
in both primary and metastatic sites [17], MF1 blockade of
VEGFR1 did not change the number of BMDCs. Collectively,
these data suggest that signaling pathways alternative to VEGFR1
are involved in BMDC infiltration in growing B16 or LLC1
tumors. Of interest, in BMT-Actb-GFP/C57BL mice, GFP
+
expression in BMDCs often co-localized with expression of Gr1
or CD11b. These BMDCs have been shown to modulate
resistance to VEGF blockade in these tumor models [25].
In summary, we show that formation of the metastatic nodules
is independent of intracellular VEGFR1 activity, since neither
pharmacologic blockade nor genetic deficiency in intracellular
VEGFR1-TK domain prevented or altered pre-metastatic BMDC
infiltration, nor spontaneous metastasis. We propose that pathways
other than VEGFR1 are activated and lead to BMDC infiltration,
and should be targeted in order to optimize anti-VEGF therapy
and prevent spontaneous metastasis.
Supporting Information
Figure S1 Primary LLC1 and B16 tumor growth kinetics after
VEGFR1 blockade. LLC1 and B16 tumors were grown in BMT-
Actb-GFP/C57BL mice treated with IgG (black solid lines) or
MF1 (blue dashed lines) (A,C) or in C57BL (WT, black solid lines)
or flt-1TK-/-/C57BL (KO, blue dashed lines) mice (B,D).
Found at: doi:10.1371/journal.pone.0006525.s001 (1.19 MB
PDF)
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